Tongsen Zheng

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Huan Wang · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
2. Xue Yang · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
3. Xiaoyu Yin · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
4. Xianze Wang · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
5. Qiang Xu · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
6. Chuntao Gao · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
7. Zhihua Li · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
8. Tao Xia · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
9. Yuejuan Cheng · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
10. Heshui Wu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
11. Rufu Chen · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
12. Deliang Fu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
13. Wenming Wu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
14. Xiaona Fan · 1 shared paper, 2024 · strength 0.16
    • Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
15. Dan Wang · 1 shared paper, 2024 · strength 0.16
    • Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
16. Hengzhen Li · 1 shared paper, 2024 · strength 0.16
    • Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
17. Changjie Lou · 1 shared paper, 2024 · strength 0.16
    • Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
18. Zhiwei Li · 1 shared paper, 2024 · strength 0.16
    • Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
19. Yanqiao Zhang · 1 shared paper, 2024 · strength 0.16
    • Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
20. Xiaoyuan Sun · 1 shared paper, 2022 · strength 0.16
    • Paper GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2022.06.006↗
21. Ke Lei · 1 shared paper, 2022 · strength 0.16
    • Paper GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2022.06.006↗
22. He Ren · 1 shared paper, 2022 · strength 0.16
    • Paper GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2022.06.006↗
23. Dehai Wu · 1 shared paper, 2019 · strength 0.06
    • Paper A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growt… DOI 10.1158/1078-0432.ccr-18-4113↗
24. Yao Liu · 1 shared paper, 2019 · strength 0.06
    • Paper A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growt… DOI 10.1158/1078-0432.ccr-18-4113↗
25. Dalong Yin · 1 shared paper, 2019 · strength 0.06
    • Paper A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growt… DOI 10.1158/1078-0432.ccr-18-4113↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.